利拉鲁肽治疗轻中度阿尔茨海默病:一项2b期临床试验
ELAD是一项多中心、随机、双盲、安慰剂对照2b期试验,纳入204例无糖尿病的轻中度阿尔茨海默病综合征患者,每日注射利拉鲁肽或安慰剂52周。主要结局脑葡萄糖代谢率两组无显著差异(差值=-0.17;95%CI:-0.39至0.06;P=0.14);ADAS-Exec评分利拉鲁肽组优于安慰剂组(0.15;95%CI:0.03-0.28;未校正P=0.01)。利拉鲁肽在非糖尿病阿尔茨海默病患者中总体安全且耐受良好。
要点
- 主要结局脑葡萄糖代谢率两组无显著差异(差值=-0.17;95%CI:-0.39至0.06;P=0.14)。
- ADAS-Exec评分利拉鲁肽组优于安慰剂组(0.15;95%CI:0.03-0.28;未校正P=0.01)。
- ADCS-ADL与CDR-SoB评分两组无显著差异。
核心结论
- 利拉鲁肽在无糖尿病的轻中度阿尔茨海默病综合征患者中总体安全且耐受良好。
- 主要结局脑葡萄糖代谢率两组无显著差异(差值=-0.17;95%CI:-0.39至0.06;P=0.14)。
研究设计与样本
- ELAD为多中心、随机、双盲、安慰剂对照2b期临床试验,纳入204例无糖尿病的轻中度阿尔茨海默病综合征患者。
- 参与者每日注射利拉鲁肽或安慰剂52周,接受氟脱氧葡萄糖正电子发射断层扫描、磁共振成像及详细神经心理评估。
主要发现
- 主要结局脑葡萄糖代谢率两组无显著差异(差值=-0.17;95%CI:-0.39至0.06;P=0.14)。
- ADAS-Exec评分利拉鲁肽组优于安慰剂组(0.15;95%CI:0.03-0.28;未校正P=0.01)。
- ADCS-ADL评分两组无显著差异(-0.58;95%CI:-3.13至1.97;未校正P=0.65)。
- CDR-SoB评分两组无显著差异(-0.06;95%CI:-0.57至0.44;未校正P=0.81)。
- 利拉鲁肽在非糖尿病阿尔茨海默病患者中总体安全且耐受良好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer's disease syndrome. 'Evaluating liraglutide in Alzheimer's disease' (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer's disease syndrome with no diabetes. Participants received daily injections of liraglutide or placebo for 52 weeks. They underwent fluorodeoxyglucose positron emission tomography, magnetic resonance imaging and detailed neuropsychometric evaluations. The primary outcome was a change in cerebral glucose metabolic rate. Secondary outcomes were safety and tolerability and cognitive changes. The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups. The secondary outcome-score on the Alzheimer's Disease Assessment Scale-Executive domain (ADAS-Exec)-performed better in liraglutide-treated patients compared to placebo (0.15; 95% confidence interval: 0.03-0.28; unadjusted P = 0.01). No significant differences were observed in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (-0.58; 95% confidence interval: -3.13 to 1.97; unadjusted P = 0.65) or Clinical Dementia Rating-Sum of Boxes (CDR-SoB) (-0.06; 95% confidence interval: -0.57 to 0.44; unadjusted P = 0.81) scores. Liraglutide was generally safe and well tolerated in non-diabetic patients with Alzheimer's disease. ClinicalTrials.gov identifier: NCT01843075 .
引用
- Edison P, Femminella GD, Ritchie C, et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nat Med. 2025. PMID: 41326666. doi:10.1038/s41591-025-04106-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。